【摘 要】
：
Objective: To retrieve and summarize the role of high mobility group protein B1 (HMGB1) and receptor for advanced glycation end product (RAGE) in proliferat
【机 构】
：
湖北医药学院附属人民医院中药药理实验室 湖北,十堰442000
【出 处】
：
2015医学前沿论坛暨第十四届全国肿瘤药理与化疗学术会议
论文部分内容阅读
Objective: To retrieve and summarize the role of high mobility group protein B1 (HMGB1) and receptor for advanced glycation end product (RAGE) in proliferation and metastasis of hepatocellular carcinoma (HCC), aiming to offer a basic data for further studies on potential molecular targets in HCC.Methods: High mobility group protein B1(HMGB1), receptor for advanced glycation end product (RAGE) and hepatocellular carcinoma (HCC) were retrieved in PubMed, CNKI, Wangfang and Chongqing VIP databases, respectively.The role of HMGB1 and RAGE in proliferation and metastasis of HCC was summarized and analyzed.Results: HMGB1 and RAGE can induce the proliferation and metastasis of HCC cells which might be the potential targets for chemotherapy.
其他文献
目的 肿瘤生长和转移与新生血管生成(angiogenesis)紧密相关。抑制血管生成已成为抗肿瘤治疗的重要策略。肿瘤血管生成抑制剂(Tumor angiogenesis inhibitor,TAI)是抗肿
目的 乳腺癌耐药蛋白(Breast cancer resistance protein,BCRP)在乳腺癌多药耐药中发挥重要作用,目前尚无关于microRNA通过直接靶向协同抑制BCRP表达参与乳腺癌细胞化疗
目的 肝癌低氧微环境所引起的肝瘤细胞对化疗、放疗不敏感,预后效果差已成为肝癌治疗的一大障碍,成为了肝癌治疗中被广泛关注和研究的问题。本文旨在研究新型FAK抑制剂CT
目的 娃儿藤碱及其类似物对多种组织来源肿瘤细胞以及多药耐药肿瘤细胞具有显著的体内、外抗肿瘤活性.密花娃儿藤碱曾在1960s进入抗肿瘤临床I期研究,因严重的神经系统毒
Purpose Dual PI3K/mTOR(phosphatidylinositol 3-kinase/mammalian target of rapamycin) inhibitors are being evaluated clinically for the treatment of tumors wi
Purpose To investigate the mechanism of pretreatment with EGFR inhibitors sensitizes cancer cells to DNA-damaging therapy.Method MTT assay was applyed to de
目的 评价新型氨肽酶(APN)抑制剂4Q联合五氟尿嘧啶(5FU)抗肝癌活性.方法 采用PLC、H7402、Hepg2三种肝癌细胞，五氟尿嘧啶(5FU) (20μ mo1/L)和乌苯美司或4Q(1.5625～400μ m
目的 观察肺腺癌胸腔积液患者证型分布情况；分离培养胸腔积液中的肿瘤细胞，观察它的生物学特性；并研究胸水中血管内皮生长因子(VEGF)的含量及其与中医证型的相关性。方法 (1
Cutaneumcarcinoma is commonly responsible for significant morbidity and mortality and the treatments have not progressed significantly in the last few years